Be part of the movement as CAR-T Therapy shapes the future of oncology.
The promise of the revolutionary oncology treatment, CAR-T therapy, has become a reality this year, with end-stage cancer patients treated on public health services across the world. As CAR-T moves into the public domain, battle has commenced in the race to effectively commercialise this ground-breaking therapy.
The CAR-T Congress is bringing together leading biotechs, late-stage researchers and global pharmaceutical leaders to promote and share research that will break down barriers in R&D through novel data. In our fourth annual congress, we are introducing a new pre-day focused on NK Cell Therapy and the event will run alongside our Vein-to-Vein Congress, so you can tailor your agenda and learn more about cell therapies and their manufacturing.
Having listened to the market demands, this year we will be bringing you even more industry-driven understanding of translational applications of the science that drives R&D in CAR-T. Tackle the next hurdles for allogeneic treatments by limiting graft vs host disease through the use of iPSC, and increase the efficacy of these treatments in solid tumours through combination therapies and solid tumour manipulation.
Talks run by biotechs, pharma and regulatory bodies, will put you in a position to make informed decisions when commercialising your CAR-T therapy.
Event name: CAR-T Congress EU 2020
Event date: 29-30 January, 2020
Event venue: London, United Kingdom
Organization: Kisaco Research
Organizer link: https://www.kisacoresearch.com/